International Society on Thrombosis and Haemostasis, Inc.
Previous Speakers in the Spotlight

As we count down to the Course, each week we highlight speakers who will participate in the 2014 Second Advanced Training Course.

Previous Speakers in the Spotlight:

Andreas Greinacher, Germany

Andreas Greinacher is an M.D. with a specialization in transfusion medicine and hemostasis. His scientific career is focused on platelet disorders, bridging immuno-hematology and hemostasis. He is working at the University Hospital Greifswald, Germany, where he is head of the Institute of Immunology and Transfusion Medicine, the clinical thrombosis and hemostasis service, the hemostasis out-patient clinic, the transfusion and stem cell service and the immuno-hematology laboratory.
Full Biography online here.

Dr. Greinacher will give two presentations at the Second Advanced Training course, including one on Diagnosis and treatment of acquired platelet disorders

Excerpt from the Presentation Abstract Below:

"Acquired platelet disorders can affect platelet number (thrombocytopenia) or platelet function (thrombocytopathy); very often, both are affected.
Thrombocytopenia: Thrombocytopenia often complicates critical illness and is associated with increased morbidity and mortality. The most frequent cause of severe thrombocytopenia in hospital-ized patients is chemotherapy-induced hypoproliferative thrombocytopenia. Several recent prospec-tive trials in these patients show: a prophylactic transfusion regimen using a transfusion trigger of 10,000 platelets/µL primarily reduces WHO grade 2 bleeding (which may be important for quality of life), but not WHO grade 3 or 4 bleeding; patients with acute leukemias benefit from a prophy-lactic transfusion regimen, while autologous stem cell transplantation may justify a therapeutic transfusion regimen. "

Selected Related Resources:

  • Stanworth SJ et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. NEJM 2013;368:1771-80.
  • Wandt H. et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380:1309-16.

Christian Gachet, France

Dr. Christian Gachet graduated as a medical doctor in 1985 and gained his Ph.D. in Pharmacology in 1991, both at the Université Louis Pasteur, Strasbourg, France. He became a Research Director at INSERM (Institut National de la Santé et de la Recherche Médicale) in 1998. Dr. Gachet is currently the Director of the INSERM Research Unit 949 and the Scientific Director at Etablissement Français du Sang-Alsace.
The focus of Dr. Gachet’s work has long been the molecular mechanisms of ADP-induced platelet activation and its inhibition by the thienopyridine compounds.
Full Biography online here.

Dr. Gachet will give two presentations at the Second Advanced Training course, including one on Diagnosis and treatment of inherited platelet disorders

Excerpt from the Presentation Abstract Below:

"Diagnosis of inherited platelet disorders is based on the bleeding case history, platelet count, blood smear, platelet function testing, and flow cytometry to examine the membrane glycoproteins. Sometimes, electron microscopy and sophisticated biochemical techniques are used, including new genetic approaches to identify known or unknown causative genes and mutations leading to the disease.
Treatment depends on the severity of the bleeding syndrome and the circumstances. It can be curative or preventive prior to surgery for example. Severe bleeding requires transfusion of platelets. Alternative treatments include DDAVP mostly used in case of Willebrand disease, antifibrinolytic agents, recombinant FVIIa or TPO mimetics. Haematopoietic stem cell transplantation and gene therapy have already been successfully used in several cases."

Selected Related Resources:

  • Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Br J Haematol. 2013 Nov 29.

  • Ware J, Corken A, Khetpal R. Platelet function beyond hemostasis and thrombosis. Curr Opin Hematol. 2013;20(5):451-6

Sabine Eichinger, Austria

Sabine Eichinger is Associate Professor of Medicine at the Medical University of Vienna, Austria, and Head of the Anticoagulation Clinic at the Department of Medicine I of the Medical University Hospital in Vienna. Dr. Eichinger received her medical and scientific training at the Department of Medicine I, Division of Haematology and Haemostasis, University of Vienna, and at the Beth Israel Hospital, Harvard Medical School, Boston, USA.Dr. Eichinger’s anticoagulation research has included investigating the mechanism of action of pro-coagulants and anticoagulants in in vitro and in vivo models, and the pathophysiology of the coagulation system in women.
Full Biography online here.

Professor Eichinger will give two presentations at the Second Advanced Training course, including one on Perioperative management in patients with risk for thrombosis

Excerpt from the Presentation Abstract Below:

"Patients at risk of thrombosis who need to undergo surgery or other invasive procedures are not only at an increased risk of thrombosis but also of bleeding. The thrombotic risk is composed by the patient’s intrinsic risk and the risk that is specific for the respective procedure. In analogy, the bleeding risk is influenced by patient characteristics and the type of surgery. Thus, for optimal perioperative management the thrombotic risk needs to be weighed against the bleeding risk."

Selected Related Resources:

  • Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012;141(2 Suppl):e326S-50S

  • Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954-62..

Sam Schulman, Canada

Sam Schulman graduated from Karolinska Institute, Stockholm, Sweden in 1977 and became a specialist in Internal Medicine in 1984, with subspecialties in Haematology and in Coagulation in 1985. His major research activities have been clinical studies in venous thromboembolism, including several randomized trials and in hemophilia and its complications. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors.
Full Biography online here.


Professor Schulman will give two presentations at the Second Advanced Training course, including one on Novel antithrombotic drugs

Excerpt from the Presentation Abstract Below:

"During the past decade many studies on highly specific, orally available anticoagulants in the treatment of venous thromboembolism (VTE) and for stroke prophylaxis in atrial fibrillation (SPAF) have been published. This story started with the first oral thrombin inhibitor, ximelagatran, but the drug was withdrawn early from the market due to liver toxicity. In 2009 the phase III studies on the next oral thrombin inhibitor were published, showing in comparison with warfarin similar or improved efficacy for SPAF and similar efficacy in treatment of VTE. There was also a reduction of some bleeding outcomes. Subsequently, the pattern has been repeated with oral direct factor Xa inhibitors. The phase III program of the first three of those agents has been fully presented and the drugs has been approved for SPAF in many jurisdictions and one drug, rivaroxaban, also for treatment and for extended secondary prophylaxis of VTE."

Related Resources:

  • Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e120S-51S.

  • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.

Björn Dahlbäck, Sweden

Björn Dahlbäck is professor of Blood Coagulation Research at Lund University, Department of Laboratory Medicine, Skåne University Hospital, Malmö, Sweden. His research on the molecular mechanisms of the protein C anticoagulant system has focused on the role of activated protein C and its cofactor protein S in the degradation of coagulation factors V and VIII.
Full Biography online here.

Professor Dahlbäck will give two presentations at the Second Advanced Training course, including one on Blood Coagulation

Excerpt from the Presentation Abstract Below:

"Primary haemostasis and blood coagulation have evolved as important defense mechanisms against bleeding. The initial occlusion of a vascular lesion by the platelet plug is temporally co-ordinated with the activation of coagulation. The coagulation pathway is carefully controlled by several anticoagulant mechanisms and under normal conditions they prevail over the procoagulant forces. Disturbances of the natural balance between the pro- and anticoagulant systems caused by genetic or acquired factors may result in bleeding or thrombotic diseases. "

Related Resources:

  • Dahlback, B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008. 112:19-27.
  • Dahlback, B, and Villoutreix, BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 2005. 25:1311-1320.

Theodore Warkentin, Canada

Theodore E. Warkentin, MD, is Professor in the Department of Medicine and the Department of Pathology and Molecular Medicine at the Michael G. DeGroote School of Medicine, McMaster University, in Hamilton, Ontario, Canada. He is also Regional Director, Transfusion Medicine, of the Hamilton Regional Laboratory Medicine Program and Hematologist, Service of Clinical Hematology, at Hamilton Health Sciences, also in Hamilton.
Full Biography online here.

Dr. Warkentin will give two presentations at the Second Advanced Training course, including one on Disseminated intravascular coagulation (DIC)

Excerpt from the Presentation Abstract Below:

"DIC is a severe form of consumptive coagulopathy in which systemic activation of hemostasis leads to widespread intravascular fibrin deposition with associated depletion of prohemostatic and anticoagulant factors, with parallel secondary fibrinolysis, potentially leading to a wide range of adverse outcomes, including thrombotic occlusion of small/mid-sized vessels, organ dysfunction/failure, and/or bleeding. One devastating sequela is 'symmetrical peripheral gangrene,' characterized by acral (distal extremity) necrosis of two (or four) limbs, despite palpable/doppler-identifiable arterial pulses."

Related Resources:

  • Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med 367:879-81, 2012.
  • Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Exp Opin Drug Saf 13:25-43, 2014.